Goldman Sachs analysts removed Fresenius Medical (FMS) Care from the firm’s European Conviction List as part of its monthly update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 60 from EUR 55 at Berenberg
- Fresenius Medical Care: Hold Rating Amid Ambitious Targets and Execution Risks
- Fresenius Medical Care Launches EUR 1 Billion Share Buyback Program
- Fresenius Medical launches its new FME Reignite strategy
- Fresenius Medical price target raised to EUR 52.50 from EUR 46.50 at Citi